Experiences with
Fludarabine, cyclophosphamide and rituximab (FCR)866 public posts
Want to take advantage of all our features? Just log in!
or
Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
An update of the long-term follow-up results from the original 300-patient FCR (fludarabine, cyclophosphamide, and rituximab) study initiated at MD Anderson in 1999, Sustained remissions in CLL after frontline treatment with very-long-term follow-up, reports ~47% of patients with mutated IGHV